New Ideal Option Data Reveal Presence of Low Potency Fentanyl in Montana
Ideal Option, a national leader in outpatient medication-assisted treatment (MAT) for addiction to opioids, stimulants and other substances, has released its 2024 Annual Outcomes Report for Montana patients. Using advanced quadrupole time-of-flight (QTOF) mass spectrometry, Ideal Option identified fentanyl analogs with up to 70% lower potency than